Kineret CAPS Post Authorisation Study

Sobi

Status: Completed

Conditions: Cryopyrin-Associated Periodic Syndromes

Treatments: Drug: anakinra (Kineret)

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02326376

ENCEPP/SDPP/6366 (Registry Identifier)

Sobi.Anakin-201

Details and patient eligibility

About

A non-interventional, post authorization safety study to evaluate the safety of Kineret in the treatment of Cryopyrin Associated Periodic Syndromes (CAPS) in routine clinical care with regard to serious infections, malignancies, injection site reactions, allergic reactions and medication errors, including re-use of syringe.

Enrollment: 12 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent by the patient and/or caregiver
• Kineret treatment will be according to the Summary of Product Characteristics (SmPC), as confirmed by the Investigator

Exclusion criteria

• None

Trial design

12 participants in 1 patient group

CAPS patients

Description:

CAPS patients treated with anakinra, using the Kineret graduated syringe

Treatment:

Drug: anakinra (Kineret)